% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Rutkowski:142116,
author = {S. Rutkowski and P. Modena and D. Williamson and K. Kerl
and K. Nysom and B. Pizer and U. Bartels and S. Puget and F.
Doz and A. Michalski and K. von Hoff and M. Chevignard and
S. Avula and M. J. Murray and S. Schönberger and T. Czech
and A. Y. N. Schouten-van Meeteren and U. Kordes and C. M.
Kramm and D. G. van Vuurden and E. Hulleman and G. O.
Janssens and G. A. Solanki and M. C. van Veelen and U.
Thomale and M. U. Schuhmann and C. Jones and F. Giangaspero
and D. Figarella-Branger and T. Pietsch and S. C. Clifford
and S. Pfister$^*$ and S. W. Van Gool},
title = {{B}iological material collection to advance translational
research and treatment of children with {CNS} tumours:
position paper from the {SIOPE} {B}rain {T}umour {G}roup.},
journal = {The lancet / Oncology Oncology},
volume = {19},
number = {8},
issn = {1470-2045},
address = {London},
publisher = {The Lancet Publ. Group},
reportid = {DKFZ-2018-02346},
pages = {e419 - e428},
year = {2018},
abstract = {Paediatric CNS tumours are the most common cause of
childhood cancer-related morbidity and mortality, and
improvements in their diagnosis and treatment are needed.
New genetic and epigenetic information about paediatric CNS
tumours is transforming the field dramatically. For most
paediatric CNS tumour entities, subgroups with distinct
biological characteristics have been identified, and these
characteristics are increasingly used to facilitate accurate
diagnoses and therapeutic recommendations. Future treatments
will be further tailored to specific molecular subtypes of
disease, specific tumour predisposition syndromes, and other
biological criteria. Successful biomaterial collection is a
key requirement for the application of contemporary
methodologies for the validation of candidate prognostic
factors, the discovery of new biomarkers, the establishment
of appropriate preclinical research models for targeted
agents, a quicker clinical implementation of precision
medicine, and for other therapeutic uses (eg, for
immunotherapies). However, deficits in organisational
structures and interdisciplinary cooperation are impeding
the collection of high-quality biomaterial from CNS tumours
in most centres. Practical, legal, and ethical guidelines
for consent, storage, material transfer, biobanking, data
sharing, and funding should be established by research
consortia and local institutions to allow optimal collection
of primary and subsequent tumour tissue, body fluids, and
normal tissue. Procedures for the collection and storage of
biomaterials and related data should be implemented
according to the individual and organisational structures of
the local institutions.},
subtyp = {Review Article},
cin = {B062 / L101},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)L101-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30102236},
doi = {10.1016/S1470-2045(18)30364-4},
url = {https://inrepo02.dkfz.de/record/142116},
}